Direct comparison
FDA Recall Classes: I vs. II vs. III
FDA assigns recall class by health risk, not the firm. Compare Class I, II, III definitions, notice rules, and what changes for your facility's response.
Written and maintained by CASRAI Editorial Board
Last updated
Ask CASRAI · included with Regulatory Radar
Ask about FDA Recall Classes: I vs. II vs. III
Ask CASRAI answers research-administration questions and cites the passages behind every claim — and says so when the corpus does not cover something, instead of guessing. It comes with a Regulatory Radar subscription at $29 a month, alongside the daily digest of regulatory changes and the dashboard of what changed.
150 questions a day, on this site, over the API, or inside your own tools through the CASRAI MCP server.
Everything CASRAI publishes — this page, the dictionary, the guides and the news — stays free to read, with no account and no card.
How do Class I, Class II, Class III compare side by side?
The table below compares Class I, Class II, Class III across 8 procurement-relevant dimensions, from fda definition (21 cfr 7.3(m)) through is it legally a "recall" at all?.
Side-by-side comparison
| Dimension | Class I | Class II | Class III |
|---|---|---|---|
| FDA definition (21 CFR 7.3(m)) | Reasonable probability that use of, or exposure to, the violative product will cause serious adverse health consequences or death | May cause temporary or medically reversible adverse health consequences, or the probability of serious adverse health consequences is remote | Not likely to cause adverse health consequences |
| Who assigns it | FDA, after reviewing the firm's health hazard evaluation — the firm does not self-classify | FDA, same process | FDA, same process |
| Typical trigger | A defect, contamination, or labeling error with a real, direct path to serious harm or death — e.g. a device malfunction that can cause a critical failure, or a life-critical dosing error | A defect that could cause temporary or reversible injury, or where serious harm is possible but unlikely — e.g. a malfunction with a reversible clinical effect | A technical or regulatory violation with no realistic health impact — e.g. a minor labeling or packaging error unrelated to safe use |
| Required "urgent" notice marking (21 CFR 7.49) | Required — the recall communication must be conspicuously marked, preferably in bold red type on both letter and envelope, and marked "urgent" | Required — same bold-red "urgent" marking requirement as Class I | Not required under 7.49's urgent-marking rule; the standard recall communication requirements (prompt notice, an instruction to stop distribution/use, a way to report back) still apply |
| Recall depth and public warning (7.42(b)(1)-(2)) | Recall strategy more often reaches the user/consumer level; a general public warning via news media is more likely, since that tool is reserved for urgent situations | Depth is assessed case by case — user-level or retail-level recalls are both common depending on the specific hazard; public warning is possible but less automatic | Recall strategy more often stops at the wholesale or retail level; a public news-media warning is uncommon given the low health risk |
| What changes for your facility's response | Treat it as an emergency: quarantine or remove the affected product from use immediately, don't wait on further instructions to stop use, and document the removal date and quantity right away | Correct or remove the product promptly, but with a less compressed timeline — confirm whether any units are currently in active use before scheduling the correction | Lower urgency, but not optional — follow the firm's return/destroy/relabel instructions, log the action, and keep the paperwork; it still has to be closed out like any other recall |
| Status reporting and termination (7.53, 7.55) | Same process as II/III — firms report recall status to the FDA district office, generally every 2–4 weeks, until FDA reviews the effectiveness data and issues a written termination notice | Same status-reporting and FDA-determined termination process | Same status-reporting and FDA-determined termination process — the lower risk class doesn't skip the recordkeeping |
| Is it legally a "recall" at all? | Yes — 21 CFR 7.3(g): removal/correction of a product FDA considers violative and would otherwise pursue enforcement against | Yes, same definition | Yes, same definition — a Class III action is still a recall under 7.3(g), legally distinct from a market withdrawal (7.3(j)) or stock recovery (7.3(k)), which involve non-violative or undistributed product and aren't recalls at all |
Common questions
Common questions about Class I vs Class II vs Class III
Does our facility get to decide, or dispute, which class a recall gets?
+
No. Classification is FDA's determination under 21 CFR 7.3(m), made after reviewing the firm's health hazard evaluation. A distributor or user facility receiving the recall notice doesn't assign or renegotiate the class — your job is to respond according to the class FDA (and the recalling firm's notice) states.
Is a Class III recall actually mandatory, or just a formality we can note and move on from?
+
It's mandatory in the sense that matters: it's still a legal recall under 21 CFR 7.3(g), and it still needs to be executed and documented — the product return, destruction, or correction has to actually happen and be logged. What's different is urgency and depth, not whether the recall is real.
What's the difference between a recall and a market withdrawal?
+
A recall (21 CFR 7.3(g)) addresses a product FDA considers violative and would otherwise take legal action against. A market withdrawal (7.3(j)) or stock recovery (7.3(k)) involves product that isn't violative in that sense — e.g. a routine removal for a reason unrelated to a violation, or recovery of stock that was never distributed to the point where a recall notice is needed. They're tracked and reported differently.
Is there a fixed deadline for completing a recall once we're notified?
+
Part 7 doesn't set one universal deadline. Firms submit periodic status reports to FDA (generally every 2–4 weeks, per 21 CFR 7.53) and FDA determines when the recall is complete and issues written termination (7.55). A Class I recall's practical urgency comes from the health-risk response expected of you, not a fixed statutory clock.
